Pharmaceuticals
Ascentage Pharma's Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia
SUZHOU, China, and ROCKVILLE, MD., Nov. 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the European Commission (EC) has granted the...
2021-11-22 21:24
1797
Bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech and Sanyou Biopharmaceuticals appearing at China International Import Expo (CIIE)
SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- At the opening ceremony of the 4th China International Import Expo (CIIE) held inShanghai on November 6, 2021, SYZJ001, a bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech Co., Ltd. and Sanyou Biopharmaceuticals (Shanghai) ...
2021-11-22 21:00
1301
TenNor Reports Positive Results of TNP-2092 Capsule for the Treatment of Liver Cirrhosis Hyperammonemia
SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- TenNor Therapeutics reports positive top-line results for TNP-2092 Capsule from a phase II clinical trial for the treatment of hyperammonemia/hepatic encephalopathy in patients with liver cirrhosis. TNP-2092 Capsule is an investigational new drug produ...
2021-11-22 21:00
1113
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals ("Hengru...
2021-11-21 17:02
2583
Successful 2020 Tang Prize Award Ceremony Highlights Laureates' Achievements and Influence
TAIPEI, Nov. 20, 2021 /PRNewswire/ -- The 2020 Tang Prize Award Ceremony took place virtually at 2p.m. (GMT+8) onNovember 20. Eight 2020 recipients of the prize from seven countries, including the U.S., the U.K.,Japan, Singapore, Bangladesh, Colombia, and Lebanon, attended this heartwarming event...
2021-11-20 15:00
2853
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma
SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Nov. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2021-11-19 19:00
2258
111, Inc. Announces Third Quarter 2021 Unaudited Financial Results
SHANGHAI, Nov. 19, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the third quart...
2021-11-19 13:31
2850
ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine
SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data today on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional...
2021-11-19 13:14
1238
China sees huge bounce in pharma rankings ahead of hybrid CPhI & P-MEC China
SHANGHAI, Nov. 18, 2021 /PRNewswire/ -- China's pharma industry has seen a record improvement in its overall score, growth potential and biologics according to new data. TheChina specific findings of the CPhI Annual Report rankings[1] are released ahead of CPhI & P-MEC China - which will take pla...
2021-11-18 15:00
1130
Inmagene files two international patent applications
SHANGHAI and SAN DIEGO and HANGZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene" or the "Company") announced that it has filed two international patent applications for its drug candidates, IMG-007 (OX40 antagonist) and IMG-008 (IL-36R antagonist). One application...
2021-11-17 18:30
1378
Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe
* The therapy aims to re-energize a patient's immune system to fight cancer
tumors
* Initial commercialization will target leading oncology centers in Germany,
France, Italy, and Spain LAKEWOOD, Colo. and SAN DIEGO, Nov. 16, 2021
/PRNewswire/ --Terumo Blood and Cell Technologies
2021-11-17 00:00
1651
Senhwa Biosciences Announces Abstract Accepted for Presentation at the 2022 ASCO Gastrointestinal Cancers Symposium
TAIPEI and SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting clinical design for their lead drug candidate...
2021-11-15 20:00
1475
Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention
JIUQUAN, China, Nov. 15, 2021 /PRNewswire/ -- Qilian International Holding
Group Limited (Nasdaq: QLI
2021-11-15 20:00
1273
Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China
SUZHOU, China, Nov. 12, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical ...
2021-11-12 14:17
1726
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
BEIJING, Nov. 12, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Goldman Sachs and Morgan Stanley to share company's latest development. Details are as follows: ...
2021-11-12 14:14
1585
PNOC Study in Childhood Brain Cancer Enrols First Patient
SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at theUniversity of Calif...
2021-11-11 21:00
2705
Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose
HANGZHOU, China, Nov. 11, 2021 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA106 was given to human subjects in a phase 1 study to investigate the safety, pharmacokinetics, and pharmacodynamics of this drug in the treatment of obesity. The study is a single dose, placeab...
2021-11-11 18:00
1239
Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed
* Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resistant prostate cancer (mCRPC). * Dosimetry data is be...
2021-11-10 22:06
1759
IASO Biotherapeutics and Innovent Biologics to Present New BCMA CAR-T Cell Therapy Data in Oral Presentation at ASH 2021
SAN JOSE, Calif., NANJING, China and SHANGHAI, Nov. 10, 2021 /PRNewswire/ --
IASO Biotherapeutics("IASO Bio")
2021-11-10 21:30
1641
I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa
* The partnership brings together the strengths of an innovative global biotech and a domestic leading pharmaceutical company specialized in and committed to pediatric medicines to accelerate the commercialization of eftansomatropin alfa * Jumpcan will pay I-Mab for a total of up to RMB 2.016...
2021-11-10 17:30
1746
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5214
